Actively Recruiting
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Led by Stanford University · Updated on 2025-05-29
120
Participants Needed
1
Research Sites
630 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
CONDITIONS
Official Title
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Upper and/or lower extremity complex regional pain syndrome (CRPS)
- On stable treatment for at least 1 month
- CRPS diagnosis for at least 1 year
- Meet the Budapest criteria for CRPS at the time of the study
You will not qualify if you...
- Known allergy to naltrexone or naloxone
- Use of prescription opioid analgesics or illegal opioid use
- Current or planned pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
B
Birute Gedrimaite
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here